Clinical Trials Logo

Filter by:
NCT ID: NCT00425919 Terminated - Diabetes Mellitus Clinical Trials

Study Evaluating PPM-204 In Subjects With Type 2 Diabetes

Start date: January 2007
Phase: Phase 2
Study type: Interventional

The purpose of this study is to learn whether PPM-204 has an effect on lowering blood glucose (blood sugar) levels and is safe in treating people with type 2 diabetes.

NCT ID: NCT00412776 Terminated - Clinical trials for Head and Neck Cancer

Study of Proxinium Plus Best Supportive Care Versus Best Supportive Care for Patients With Advanced Head and Neck Cancer

Start date: December 2005
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to compare the safety and efficacy of Proxinium plus best supportive care with best supportive care only for patients with squamous cell head and neck cancer.

NCT ID: NCT00408473 Terminated - Atrial Fibrillation Clinical Trials

Comparative Study of Flecainide CR and Placebo in the Early Treatment of Atrial Fibrillation.

Start date: n/a
Phase: Phase 4
Study type: Interventional

The purpose of the study is to assess the efficacy of flecainide controlled release (CR) in the prevention of recurrent AF during 9 months of active treatment compared to placebo in patients with only one documented AF episode.

NCT ID: NCT00391066 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

LUCID
Start date: November 2006
Phase: Phase 2
Study type: Interventional

This is a randomized (1:1), open-label, multicenter, active-controlled study in patients with previously treated CD23+ and CD20+ relapsed CLL. Patients will receive treatment with either lumiliximab in combination with FCR or FCR alone.

NCT ID: NCT00387686 Terminated - Fractures Clinical Trials

A Phase 2/3 Multicenter, Controlled Trial Of rhBMP-2/CPM In Tibial Fractures

Start date: November 2006
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this study is to assess whether a single dose of rhBMP-2/CPM administered at the fracture site via percutaneous injection, in combination with standard of care, accelerates fracture union and return to normal function in subjects who have a closed diaphyseal tibial fracture when compared to standard of care alone.

NCT ID: NCT00366795 Terminated - Liver Cirrhosis Clinical Trials

Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

SPARe-2
Start date: August 2006
Phase: Phase 3
Study type: Interventional

Primary: To evaluate the efficacy of satavaptan in the absence of concomitant diuretic drugs in reducing the recurrence of ascites. Secondary: To evaluate the tolerability and safety of satavaptan in the absence of concomitant diuretic drugs over a 52-week treatment period in patients with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).

NCT ID: NCT00361868 Terminated - Dyslipidemia Clinical Trials

Fenofibrate and Metformin Fixed Combination vs Rosiglitazone - FAME ROSI

Start date: June 2006
Phase: Phase 3
Study type: Interventional

Under conditions of first-line drug treatment in antidiabetic drug naïve/drug free patients with type 2 diabetes mellitus and dyslipidemia, to show that :- the efficacy of a fixed combination (FC) of fenofibrate and metformin on glycemic control is not inferior to that of rosiglitazone and the efficacy of FC of fenofibrate and metformin on triglyceride control is superior to that of rosiglitazone.

NCT ID: NCT00359437 Terminated - Liver Cirrhosis Clinical Trials

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

SPARe-1
Start date: July 2006
Phase: Phase 3
Study type: Interventional

Primary To evaluate the efficacy of satavaptan on top of diuretic drugs in reducing the recurrence of ascites. Secondary To evaluate the tolerability and safety of satavaptan on top of diuretic drugs over a 52-week treatment period in patients with cirrhosis of the liver and recurrent ascites. The one-year double blind placebo controlled period is extended up to 2 years in a long term safety study (PASCCAL-2).

NCT ID: NCT00311896 Terminated - Cancer Clinical Trials

Efficacy & Safety of Prophylaxis With Bemiparin in Cancer Patients With a Central Venous Catheter (BECAT)

Start date: July 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of the subcutaneous administration for 45 days of Bemiparin (3,500 UI/day) in cancer patients with a CVC, to prevent CVC-related deep venous thrombosis (CVC-DVT)

NCT ID: NCT00296010 Terminated - Breast Cancer Clinical Trials

Liposomal Doxorubicin Compared With Observation or Cyclophosphamide and Methotrexate in Treating Older Women Who Have Undergone Surgery for Breast Cancer

CASA
Start date: August 2005
Phase: Phase 3
Study type: Interventional

RATIONALE: Drugs used in chemotherapy, such as methotrexate, cyclophosphamide, and liposomal doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. It is not yet known whether giving liposomal doxorubicin after surgery is more effective than observation or cyclophosphamide and methotrexate in treating breast cancer. PURPOSE: This randomized phase III trial is studying liposomal doxorubicin to see how well it works compared with observation or cyclophosphamide and methotrexate in treating older women who have undergone surgery for breast cancer.